World J Mens Health.  2015 Dec;33(3):125-129. 10.5534/wjmh.2015.33.3.125.

Testosterone Replacement Therapy and Prostate Cancer Incidence

• Eisenberg

• KMID: 2405140
• DOI: http://doi.org/10.5534/wjmh.2015.33.3.125

Abstract

While early studies demonstrated a positive association between testosterone and prostate cancer, evidence on the nature of the relationship has evolved with time and newer data. Studies examining links between baseline testosterone levels as well as testosterone therapy and incident prostate cancer, reveal a more complex relationship. Moreover, investigators have reported their initial experiences with supplementing testosterone in men with a history of both treated and untreated prostate cancer.

Keyword

Androgens; Hypogonadism; Prostatic neoplasms; Testosterone

MeSH Terms

Androgens
Humans
Hypogonadism
Incidence*
Male
Prostate*
Prostatic Neoplasms*
Research Personnel
Testosterone*
Androgens
Testosterone

Reference

1. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1:293–297.

2. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur Urol. 2006; 50:935–939. PMID: 16875775.

3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29. PMID: 25559415.

4. Moyer VA. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157:120–134. PMID: 22801674.

5. Bhasin S, Storer TW, Berman N, Yarasheski KE, Clevenger B, Phillips J, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997; 82:407–413. PMID: 9024227.

6. Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord. 2011; 11:18. PMID: 22044661.

7. Kenny AM, Kleppinger A, Annis K, Rathier M, Browner B, Judge JO, et al. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty. J Am Geriatr Soc. 2010; 58:1134–1143. PMID: 20722847.

8. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory. J Urol. 2011; 186:1005–1011. PMID: 21788049.

9. Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med. 2011; 8:3204–3213. PMID: 21834870.

10. Endogenous Hormones and Prostate Cancer Collaborative Group. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008; 100:170–183. PMID: 18230794.

11. Shin BS, Hwang EC, Im CM, Kim SO, Jung SI, Kang TW, et al. Is a decreased serum testosterone level a risk factor for prostate cancer? A cohort study of Korean men. Korean J Urol. 2010; 51:819–823. PMID: 21221200.

12. Morgentaler A, Rhoden EL. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less. Urology. 2006; 68:1263–1267. PMID: 17169647.

13. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. Eur Urol. 2012; 62:757–764. PMID: 22658758.

14. Yano M, Imamoto T, Suzuki H, Fukasawa S, Kojima S, Komiya A, et al. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening. Eur Urol. 2007; 51:375–380. PMID: 17005316.

15. Lane BR, Stephenson AJ, Magi-Galluzzi C, Lakin MM, Klein EA. Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology. 2008; 72:1240–1245. PMID: 18692874.

16. Porcaro AB, Petrozziello A, Ghimenton C, Migliorini F, Sava T, Caruso B, et al. Associations of pretreatment serum total testosterone measurements with pathology-detected Gleason score cancer. Urol Int. 2014; 93:269–278. PMID: 24334919.

17. Cabral PH, Iwamoto MW, Fanni VS, Barros Lda R, Cardoso SN, Mello LF, et al. Study of testosterone as a predictor of tumor aggressiveness in patients with prostate cancer. Int Braz J Urol. 2013; 39:173–181. PMID: 23683664.

18. Xylinas E, Ploussard G, Durand X, Fabre A, Salomon L, Allory Y, et al. Low pretreatment total testosterone (< 3 ng/mL) predicts extraprostatic disease in prostatectomy specimens from patients with preoperative localized prostate cancer. BJU Int. 2011; 107:1400–1403. PMID: 21050360.

19. Koo JM, Shim BS. Significance of serum testosterone for prostate-specific antigen (PSA) elevation and prediction of prostate cancer in patients with PSA above 10 ng/ml. Korean J Urol. 2010; 51:831–835. PMID: 21221202.

20. Morote J, Ramirez C, Gómez E, Planas J, Raventós CX, de Torres IM, et al. The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness. BJU Int. 2009; 104:486–489. PMID: 19220251.

21. Kim HJ, Kim BH, Park CH, Kim CI. Usefulness of preoperative serum testosterone as a predictor of extraprostatic extension and biochemical recurrence. Korean J Urol. 2012; 53:9–13. PMID: 22323967.

22. Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, Briganti A, et al. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. World J Urol. 2013; 31:275–280. PMID: 22441310.

23. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, et al. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2003; 169:1670–1675. PMID: 12686805.

24. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2004; 89:2085–2098. PMID: 15126525.

25. Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of testim(r) 1% testosterone gel in hypogonadal men. Rev Urol. 2004; 6(Suppl 6):S22–S29. PMID: 16985908.

26. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci. 2005; 60:1451–1457. PMID: 16339333.

27. Feneley MR, Carruthers M. Is testosterone treatment good for the prostate? Study of safety during long-term treatment. J Sex Med. 2012; 9:2138–2149. PMID: 22672563.

28. Eisenberg ML, Li S, Betts P, Herder D, Lamb DJ, Lipshultz LI. Testosterone therapy and cancer risk. BJU Int. 2015; 115:317–321. PMID: 24684569.

29. Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003; 170:2348–2351. PMID: 14634413.

30. Pastuszak AW, Pearlman AM, Lai WS, Godoy G, Sathyamoorthy K, Liu JS, et al. Testosterone replacement therapy in patients with prostate cancer after radical prostatectomy. J Urol. 2013; 190:639–644. PMID: 23395803.

31. Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007; 109:536–541. PMID: 17183557.

32. Pastuszak AW, Khanna A, Badhiwala N, Morgentaler A, Hult M, Conners WP, et al. Testosterone therapy after radiation therapy for low, intermediate and high risk prostate cancer. J Urol. 2015; 194:1271–1276. PMID: 26025500.

33. Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009; 103:62–64. PMID: 18671790.

34. Pastuszak AW, Pearlman AM, Godoy G, Miles BJ, Lipshultz LI, Khera M. Testosterone replacement therapy in the setting of prostate cancer treated with radiation. Int J Impot Res. 2013; 25:24–28. PMID: 22971614.

35. Leibowitz RL, Dorff TB, Tucker S, Symanowski J, Vogelzang NJ. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2010; 105:1397–1401. PMID: 19912179.

36. Morgentaler A, Lipshultz LI, Bennett R, Sweeney M, Avila D Jr, Khera M. Testosterone therapy in men with untreated prostate cancer. J Urol. 2011; 185:1256–1260. PMID: 21334649.

37. Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol. 2009; 55:310–320. PMID: 18838208.

38. Salonia A, Abdollah F, Capitanio U, Suardi N, Gallina A, Castagna G, et al. Circulating sex steroids and prostate cancer: introducing the time-dependency theory. World J Urol. 2013; 31:267–273. PMID: 23283410.

39. Salonia A, Abdollah F, Capitanio U, Suardi N, Briganti A, Gallina A, et al. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. Clin Cancer Res. 2012; 18:3648–3657. PMID: 22589393.

40. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:2536–2559. PMID: 20525905.